Home » Psychedelics in Europe

Psychedelics in Europe

psychedelics in Europe PsychedeliCare

Europe has left behind decades of absolute prohibition. In less than two years, the continent has gone from criminalising psychedelics to integrating them — cautiously, but decisively — into its mental health systems. This is not a marginal trend but a transformation backed by the European Union, national governments and citizens’ movements.

PsyPal: the first EU-funded project

PsyPal is the first European study funded with public EU money to investigate psilocybin-assisted therapy, with a budget of 6.5 million euros. Launched in 2024, PsyPal focuses on palliative care: it assesses whether psilocybin can relieve existential anxiety and depression in patients with terminal illness. The consortium brings together 19 European partners, including hospitals, universities and ethics experts.

This project marks a milestone: for the first time, Europe is investing in psychedelics not as drugs, but as therapeutic tools with demonstrable clinical potential.

Germany: the first country to legalise compassionate use

In July 2025, Germany became the first country in the European Union to implement a legal framework for the therapeutic use of psilocybin, a historic milestone in the continent’s drug policy. The reform, driven by a parliamentary coalition that included the Greens, the SPD and part of the opposition, allows the compassionate use of psilocybin in patients diagnosed with treatment-resistant depression (TRD) — that is, those who have not responded to at least two different antidepressants after adequate trials.

Unlike purely experimental models, the German programme does not require participation in clinical trials. Specialist psychiatrists can apply for authorisation from the regional health authorities (Landesbehörden) to administer psilocybin in controlled clinical settings, provided they meet strict protocols for preparation, supervision during the session and follow-up after the experience.

The drug used is pharmaceutical-grade synthetic psilocybin, produced to GMP (Good Manufacturing Practice) standards, which guarantees purity, precise dosing and traceability. Sessions take place in accredited clinics, with multidisciplinary teams that include psychiatrists, psychotherapists and nurses trained in non-directive support.

Czech Republic: psychedelic therapy for all

From 1 January 2026, the Czech Republic will implement a legal framework allowing the therapeutic use of psilocybin for resistant depression. The Czech Parliament approved the reform by an overwhelming majority in 2025, making the country the third in the world — after Australia and the United States (in specific states) — to legalise psilocybin for medical purposes. The reform also includes legalising home cultivation of up to three cannabis plants, showing a comprehensive approach to mental health and bodily autonomy.

During the 1950s and 1960s, Czech researchers — such as the psychiatrist Stanislav Grof, a world pioneer in LSD-assisted therapy — carried out hundreds of clinical sessions with psychedelic substances at the Prague Psychiatric Institute. After the global prohibition of the 1970s that research was interrupted, but it never disappeared entirely. Over the past two decades, universities such as Charles University and research centres in Brno have resumed preclinical studies with psilocybin, laying the groundwork for the current legal framework.

PsychedeliCare: the voice of European citizens

On 14 January 2025, PsychedeliCare, the first European Citizens’ Initiative (ECI) devoted to psychedelic-assisted therapies, was officially launched. Registered by the European Commission on 11 September 2024, its aim was to collect one million signatures before 13 January 2026 to demand legal, safe, affordable and equitable access to these therapies across the EU.

Although the final deadline has now passed without reaching the target, the campaign has made a growing social demand visible and laid the groundwork for future legislative action. The European Commission has until May 2026 to respond formally to the initiative.

Psychedelicare.eu logo with a gradient mushroom icon above the name

Switzerland: Europe’s ethical laboratory

While other European countries are only just beginning to regulate psychedelics, Switzerland has spent decades building a unique model of controlled, ethical and clinical access. Thanks to an exception in its Narcotics Act (Betäubungsmittelgesetz), since 1938 — and in a more structured way since the 1990s — Swiss doctors can apply for special authorisations to use banned substances, including LSD, MDMA and psilocybin, for therapeutic purposes.

This mechanism, known as the “compassionate use permit” (Ausnahmebewilligung), allows psychiatrists and therapists to treat patients with severe disorders — such as complex PTSD, resistant depression or existential anxiety in terminal illness — when all conventional treatments have failed. Unlike clinical trials, these are real, documented and supervised treatments, with long-term follow-up.

One of the best-known centres is the University of Zurich psychiatric clinic, where researchers such as Franz Vollenweider have published landmark studies on the neurological effects of psilocybin since the late 1990s. But there are also dozens of independent therapists in cities such as Basel, Bern and Geneva who, under strict federal supervision, offer sessions embedded in psychotherapeutic processes lasting several months.

Spain: between prohibition and the community network

Unlike Germany, the Czech Republic or Switzerland, Spain has not yet taken any official regulatory steps to legalise the therapeutic use of psychedelics. Psilocybin, LSD, DMT and other substances remain controlled, which means criminal penalties for possession, cultivation or distribution, even for personal or therapeutic purposes. In practice, however, Spain has become one of the most active epicentres in Europe for non-medicalised psychedelia, thanks to a combination of cultural tolerance, networks of mutual care and a growing ecosystem of ethical training.

Towards an ecology of consciousness

The psychedelic transformation in Europe is a symptom of a deeper crisis: the collapse of the hegemonic biomedical model of mental health. For decades, Western psychiatry has treated mental disorders as isolated chemical dysfunctions, ignoring the existential, relational and spiritual dimensions of human suffering. Psychedelics, by revealing the plasticity of consciousness and the possibility of reconfiguring inner narratives, demand something radical: not just new drugs, but new ways of being together, of listening, of accompanying.

Advances in Germany, Czechia and Switzerland show that regulation is possible, but they also carry warnings. If access is reduced to a patented pharmaceutical product, given in elite clinics and stripped of its ritual or communal dimension, we risk domesticating what is, in essence, disruptive. That is why the value of citizens’ initiatives such as PsychedeliCare — even though it did not reach a million signatures — lies in having put social justice at the centre of the debate: equitable access, bodily autonomy, a diversity of therapeutic models and community participation are not ornamental extras but sine qua non conditions.

In this context, Spain is at a symbolic crossroads. It has the chance to learn from others’ mistakes — excessive medicalisation, the exclusion of non-Western knowledge, the privatisation of care — and to propose a hybrid model: one that combines scientific rigour with the wisdom of community practices, and that respects both human rights and the ecosystems of mutual care that already exist. It is not a matter of choosing between science and spirituality, between law and freedom, but of weaving bridges between artificially separated worlds.

To thrive, the European psychedelic revolution will have to include not only patients but also facilitators, independent researchers, philosophers, artists and those who practise with these substances outside hospitals. In the end, what is at stake on the board is not how to cure depression, but how we conceive the human mind. Do we see it as a biochemical machine to be repaired, or as a living landscape to explore with respect, curiosity and community support? This is the moment to choose between a psychedelia for a select few and a transformation accessible to all. Europe has opened the door: now it must make sure no one is left outside.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU